In the plenary session on Wednesday morning, I was able to see Prof. Andrew Grulich from the Kirby Institute present information about maximising the population-level impact of PrEP. Initially he spoke about where we have come with PrEP from 2010 with the results from iPrEx study released through to 2012 US FDA approval, 2015 results from Ipergay and Proud studies and 2016 TGA approval in Australia. The PROUD and Ipergay studies show 86% efficacy in adherent individuals, research shows that adherence issues when measured in rectums is more forgiving than in vaginal mucosa where daily adherence to PrEP is more important - but notes no studies have been done in women.
PrEP Activism has highlighted what an important individual and population based intervention PrEP is, and education, demand building and advocacy for widespread availability has lead to @70% uptake in eligible high risk men in NSW and similarly in San Francisco. San Francisco has reported a 50% decrease in new diagnoses (not incidence).
Challenges continue to be in equitable access to PrEP, and identified young people and ethic minority groups being not well represented in PrEP uptake cohorts.
Increases in STIs are counterbalanced by increased testing and shorter duration of infection.
This talk inspires me to get back to work and recruit more clients to the QPrEP trial in Brisbane.